Pyxis Oncology, Inc. (PYXS)

Pyxis Oncology's stock has experienced notable events and fluctuations in the past six months. The stock price increased by 18.46% in the past month and 33.91% year-to-date as of early February 2026, but decreased by 61.88% over the past three months. In September 2025, PYXS gained 48% over four weeks, with a potential bullish breakout indicated by a "golden cross" technical chart pattern. On December 18, 2025, the stock plummeted by 49.9% in premarket trading following the release of early-stage cancer drug data. In December 2025, H.C. Wainwright raised its price target for PYXS to $7.00 from $5.00, while RBC Capital lowered its price target to $5.00 from $8.00. Effective February 2, 2026, Thomas Civik was appointed Interim Chief Executive Officer, replacing Dr. Lara Sullivan.

As a clinical-stage biotechnology company without commercialized products, there is no information available regarding demand seasonality for Pyxis Oncology's products or services.

Pyxis Oncology, Inc. is a clinical-stage biotechnology company focused on targeted oncology therapies for difficult-to-treat cancers, operating within the Medical sector, specifically the Pharmaceutical Products and Drug Discovery industries. The company focuses on antibody-drug conjugates (ADCs) and immunotherapies (IO). Its major product candidates include PYX-201, an ADC in Phase 1 trials for solid tumors; PYX-106, an immuno-oncology antibody in Phase 1 studies for advanced solid tumors; and PYX-107, a CD40 agonist antibody in Phase 2 clinical trials. The company also has in-license agreements with Pfizer Inc. and Biosion USA, Inc.

Pyxis Oncology, Inc. is headquartered in Boston, Massachusetts, United States, with reported sales activity within the United States in 2020.

Pyxis Oncology has received a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.57. MarketBeat's MarketRank™ scored Pyxis Oncology higher than 65% of evaluated companies in the medical sector. Concerns exist regarding potential toxicity, insufficient efficacy signals, negative regulatory developments, and financial challenges. The company's stock price has been highly volatile over the past three months.

Pyxis Oncology, Inc. has 104 institutional owners and shareholders holding a total of 28,678,906 shares. Major institutional owners include Pfizer Inc., Laurion Capital Management LP, and Vanguard Group Inc. Individual owners include Lara Sullivan, Pamela Ann Connealy, and Jitendra Wadhane, with Lara Sullivan owning the most shares among individuals. Approximately 3.85% of the company's stock is owned by institutional investors, 10.26% by insiders, and 4.12% by public companies and individual investors.